These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 312217

  • 1. Lymphocyte responsiveness to urinary glycosaminoglycan in systemic scleroderma.
    Ishikawa H, Hattori A.
    Dermatologica; 1979; 158(5):328-33. PubMed ID: 312217
    [Abstract] [Full Text] [Related]

  • 2. Scleroderma-inducing glycosaminoglycan in the urine of patients with systemic scleroderma.
    Ishikawa H, Saito Y, Yamakage A, Kitabatake M.
    Dermatologica; 1978; 156(4):193-204. PubMed ID: 564296
    [Abstract] [Full Text] [Related]

  • 3. [Behavior of urinary acid mucopolysaccharides in dermatological collagen diseases].
    Rossi A.
    G Ital Dermatol Minerva Dermatol; 1969 Dec; 44(12):641-5. PubMed ID: 4243640
    [No Abstract] [Full Text] [Related]

  • 4. Biochemical characterization of scleroderma-inducing glycosaminoglycan.
    Ishikawa H, Kitabatake M, Akiyama F.
    Acta Derm Venereol; 1988 Dec; 68(5):378-84. PubMed ID: 2461019
    [Abstract] [Full Text] [Related]

  • 5. An approach to experimental scleroderma, using urinary glycosaminoglycans from patients with systemic scleroderma.
    Ishikawa H, Suzuki S, Horiuchi R, Sato H.
    Acta Derm Venereol; 1975 Dec; 55(2):97-107. PubMed ID: 48324
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Urinary excretion of mucopolysaccharides in patients with collagen diseases (author's transl)].
    Kreysel HW, Köhler A.
    Dermatologica; 1974 Dec; 148(1):19-27. PubMed ID: 4275497
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Serum effects of mitogenic reactivity in subjects with systemic lupus erythematosus, rheumatoid arthritis and scleroderma. Technical considerations and lack of correlation with anti-lymphocyte antibodies.
    Horwitz DA, Garrett MA, Craig AH.
    Clin Exp Immunol; 1977 Jan; 27(1):100-10. PubMed ID: 849643
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Antibodies against extractable nuclear antigens (ENA) in systemic scleroderma.
    Jabłońska S, Błaszczyk M, Górkiewicz A, Jarzabek-Chorzelska M, Rzesa G, Chorzelski T.
    Arch Immunol Ther Exp (Warsz); 1978 Jan; 26(1-6):765-8. PubMed ID: 312085
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.